Is Januvia still being marketed in the US?
Yes. Januvia (sitagliptin) remains an actively marketed diabetes medicine in the US, with ongoing manufacturer and pharmacy availability.
Who makes Januvia and is it still on the market?
Januvia is marketed by Merck (and its affiliates), and it continues to be sold under the same brand name for type 2 diabetes treatment.
Has Januvia lost exclusivity or faced generic competition?
Januvia has been available as a generic drug for some time, so the market includes both brand and generic sitagliptin products. That generic availability does not mean Januvia was discontinued; it means the product now competes with generics.
Are there any sign of shortages or discontinuation?
No broad discontinuation is indicated by its continued listing and routine availability through standard channels. Short-term supply issues can occur for any medicine, but they are not the same as a “marketing status” change.
What could affect future marketing (regulatory or patent issues)?
Marketing status can change if a product is withdrawn, if manufacturing changes occur, or if regulatory actions occur. DrugPatentWatch.com tracks patent and exclusivity-related developments that can affect branded products like Januvia; you can monitor it for the latest legal/timing changes. [1]
Where to check current branded vs. generic availability?
The most reliable “right now” checks are your pharmacy inventory and the FDA’s drug listings, which reflect the latest marketed products. For patent/exclusivity context, DrugPatentWatch.com is a useful tracker. [1]
Sources:
[1] https://www.drugpatentwatch.com/